IL33 and neoplasm: More recent studies showed that IL-33 can regulate cytokines to mobilize Type 2 innate lymphoid cells (ILC2) from the lung and other tissues into tumor beds where they orchestrate tumor immune-surveillance in cooperation with dendritic cells to promote cytolytic T cell responses, thereby enhancing anti-cancer immunity and controlling metastasis [98].